By Colin Kellaher
Pfizer shares moved lower in premarket trading Monday after the drugmaker said it is scrapping its experimental weight-loss pill danuglipron, keeping the company on the sidelines of the booming obesity market.
Shares of the New York company, which closed Friday at $21.91, were recently down 1.9% at $21.50 in premarket trading.
Pfizer said the move follows a review of the program's clinical data, including the case of a single participant in a dose-optimization study who experienced a potential drug-induced liver injury that resolved after discontinuing danuglipron.
Pfizer previously ended a study of a twice-daily version of danuglipron after disappointing trial results in which there were too many side effects.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 14, 2025 06:54 ET (10:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.